StreetInsider.com News Articles

Form 4/A Surgery Partners, Inc. For: Aug 18 Filed by: DeLuca Teresa

Thu, 20 Aug 2026 18:10:00 -0400

si-local-file:///var/storage/secattach/20260820/26957364.html

Form 4/A Surgery Partners, Inc. For: Aug 18 Filed by: DeLuca Teresa

Thu, 20 Aug 2026 18:10:00 -0400

si-local-file:///var/storage/secattach/20260820/26957364.html

Form 4 Surgery Partners, Inc. For: Aug 18 Filed by: DeLuca Teresa

Wed, 19 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260819/26950307.html

Form 4 Surgery Partners, Inc. For: Aug 18 Filed by: DeLuca Teresa

Wed, 19 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260819/26950307.html

Form SCHEDULE 13G Surgery Partners, Inc. Filed by: KING STREET CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 12:56:00 -0400

si-local-file:///var/storage/secattach/20260814/26928099.html

Form SCHEDULE 13G Surgery Partners, Inc. Filed by: KING STREET CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 12:56:00 -0400

si-local-file:///var/storage/secattach/20260814/26928099.html

Cantor Fitzgerald Reiterates Overweight Rating on Surgery Partners (SGRY), Highlights Improved Cash Conversion

Tue, 11 Aug 2026 09:49:48 -0400

Cantor Fitzgerald analyst Sarah James reiterated an Overweight rating and $18.00 price target on Surgery Partners (NASDAQ: SGRY).

The analyst commented, "We maintain our Overweight rating on SGRY, as the Idaho Falls divestiture improves cash conversion, with its impact under-appreciated by the market. The sale underpins an EBITDA outlook bridge, accretive as reported on both a normalized & organic basis, accelerating ex-ID Falls organic growth by 110bps. Beyond 0.3x leverage relief, management estimates the facility's removal to lift FCF conversion is roughly 3%. Similar to peers, volume growth stayed relatively flat at 0.3% while same-facility revenue grew 5.0%, emphasizing the acuity

Surgery Partners (SGRY) PT Raised to $19 at TD Cowen

Tue, 11 Aug 2026 08:05:04 -0400

TD Cowen analyst Ryan Langston raised the price target on Surgery Partners (NASDAQ: SGRY) to $19.00 (from $17.00) while maintaining a Buy rating.

Surgery Partners (SGRY) Reiterated at Buy by Benchmark as Guidance Maintained

Tue, 11 Aug 2026 08:01:36 -0400

Benchmark analyst Bill Sutherland reiterated a Buy rating and $24.00 price target on Surgery Partners (NASDAQ: SGRY).

The analyst commented, " We reiterate our Buy rating and $24 PT following yesterday’s solid 2Q print and reaffirmation of full-year guidance. Management provided further details about the expected sale of its two Idaho Falls community hospitals for estimated proceeds of ~$795M. The transaction is expected to close in the next several weeks and represents the largest step in SGRY’s portfolio optimization strategy intended to sharpen the focus on short-stay surgery facilities, improve EBITDA cash conversion and reduce leverage. For the year, AEBITDA margin

Surgery Partners (SGRY) PT Lowered to $19 at RBC Capital

Tue, 11 Aug 2026 07:58:31 -0400

RBC Capital analyst Ben Hendrix lowered the price target on Surgery Partners (NASDAQ: SGRY) to $19.00 (from $20.00) while maintaining a Outperform rating.

Form 10-Q Surgery Partners, Inc. For: Jun 30

Mon, 10 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260810/26898092.html

Form 10-Q Surgery Partners, Inc. For: Jun 30

Mon, 10 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260810/26898092.html

Surgery Partners, Inc. (SGRY) Misses Q2 EPS by 18c ; Offers Guidance

Mon, 10 Aug 2026 07:54:59 -0400

Surgery Partners, Inc. (NASDAQ: SGRY) reported Q2 EPS of ($0.12), $0.18 worse than the analyst estimate of $0.06. Revenue for the quarter came in at $848.9 million versus the consensus estimate of $830.05 million.

2026 Guidance

Full year 2026 revenue guidance reaffirmed to be in the range of $3.35 billion to $3.45 billion vs consensus $3.41 billion.

For earnings history and earnings-related data on Surgery Partners, Inc. (SGRY) click here.

Form 8-K Surgery Partners, Inc. For: Aug 10

Mon, 10 Aug 2026 07:32:00 -0400

si-local-file:///var/storage/secattach/20260810/26894425.html

Form 8-K Surgery Partners, Inc. For: Aug 10

Mon, 10 Aug 2026 07:32:00 -0400

si-local-file:///var/storage/secattach/20260810/26894425.html

Surgery Partners, Inc. Announces Second Quarter 2026 Results Reaffirms Full Year 2026 Guidance

Mon, 10 Aug 2026 07:30:00 -0400

BRENTWOOD, Tenn., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the second quarter ended June 30, 2026.

Second Quarter 2026 Financial Highlights

(All comparisons are year-over-year unless otherwise noted)

Revenue increased 2.7% for the second quarter
- Same-facility revenues increased 5.0% for the second quarter
- Same-facility cases increased 0.3% for the second quarter
Net loss attributable to Surgery Partners, Inc. was $15.0 million for the second quarter